Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction

被引：0
|
作者：
Jessica S. Fortin
Matthew J. Benskey
Keith J. Lookingland
Jon S. Patterson
Erin B. Howey
John L. Goudreau
Harold C. Schott
机构：
[1] Michigan State University,Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine
[2] Michigan State University,Department of Pharmacology and Toxicology, Neuroscience Program, College of Veterinary Medicine
[3] Michigan State University,Neurology and Ophthalmology, College of Osteopathic Medicine
[4] Michigan State University,Department of Large Animal Clinical Sciences, College of Veterinary Medicine
来源：
BMC Veterinary Research | / 16卷
关键词：
Dopamine agonist; Equine; Parkinson disease animal model; Pituitary pars intermedia adenoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 29 条
  • [1] Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction
    Fortin, Jessica S.
    Benskey, Matthew J.
    Lookingland, Keith J.
    Patterson, Jon S.
    Howey, Erin B.
    Goudreau, John L.
    Schott, Harold C., II
    BMC VETERINARY RESEARCH, 2020, 16 (01)
  • [2] Does pergolide therapy prevent laminitis in horses diagnosed with pituitary pars intermedia dysfunction?
    Knowles, E. J.
    EQUINE VETERINARY EDUCATION, 2019, 31 (05) : 278 - 280
  • [3] Lamellar pathology in horses with pituitary pars intermedia dysfunction
    Karikoski, N. P.
    Patterson-Kane, J. C.
    Singer, E. R.
    McFarlane, D.
    McGowan, C. M.
    EQUINE VETERINARY JOURNAL, 2016, 48 (04) : 472 - 478
  • [4] Pituitary pars intermedia dysfunction in horses associated to pituitary adenoma
    Gris, Anderson H.
    Bianchi, Ronaldo M.
    Schwertz, Claiton I.
    Piva, Manoela M.
    Richter, Gabriela
    Sonne, Luciana
    Driemeier, David
    Pavarini, Saulo P.
    PESQUISA VETERINARIA BRASILEIRA, 2023, 43
  • [5] Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction
    Rendle, D., I
    Doran, G.
    Ireland, J.
    Edwards, S.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2019, 68 : 135 - 141
  • [6] Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction
    Huang, Luoyi
    Palmieri, Chiara
    Bertin, Francois-Rene
    RESEARCH IN VETERINARY SCIENCE, 2022, 152 : 427 - 433
  • [7] Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses
    Miller, A. B.
    Loynachan, A. T.
    Bush, H. M.
    Hart, K. A.
    Barker, V. D.
    Campana-Emard, A. G.
    Grubbs, S. T.
    Adams, A. A.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 74
  • [8] Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review
    Tatum, R. C.
    McGowan, C. M.
    Ireland, J. L.
    VETERINARY JOURNAL, 2020, 266
  • [9] Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy
    Banse, H. E.
    Whitehead, A. E.
    McFarlane, D.
    Chelikani, P. K.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 76
  • [10] Periodontal structures in horses with pituitary pars intermedia dysfunction: A histological evaluation
    Zapf, Anne Maria
    Fey, Kerstin
    Buettner, Kathrin
    Groef, Manuela
    Staszyk, Carsten
    FRONTIERS IN VETERINARY SCIENCE, 2023, 10
123